Literature DB >> 11772481

Buprenorphine prescription by general practitioners in a French region.

X Thirion1, V Lapierre, J Micallef, E Ronflé, A Masut, V Pradel, C Coudert, J C Mabriez, J L Sanmarco.   

Abstract

Since 1996 French general practitioners (GPs) may prescribe sublingual buprenorphine tablets as maintenance treatment for opiate dependence. The computerised data management of the main French health reimbursement system now allows surveillance of the use of this drug, and how it is prescribed. The purpose of this study is to determine the profile of maintained patients, prescribed doses, associated psychotropic treatments and how practitioners prescribe these treatments. This study analyses the 11186 buprenorphine prescriptions electronically transmitted for reimbursement between September and December 1999 in a specific French region. It was found that the 2078 treated patients consumed a mean of 11.5 mg of buprenorphine per day and 12% of them procured prescriptions from more than two prescribers. 43% of maintained patients had an associated benzodiazepine prescription, mainly flunitrazepam, often on the same prescription form. 61% of patients had regular follow-up, others had occasional consultations (21%) and another 18% had deviant maintenance treatment (more than two prescribers or more than 20 mg per day of daily buprenorphine dose). Benzodiazepine consumption was much higher in the 'deviant group' (71.4%). 85% of buprenorphine prescriptions were made by GPs. 21% of GPs prescribed buprenorphine and 61% of those had only one or two maintained patients. Buprenorphine prescription by French GPs is a procedure with no particular requirements, allowing many patients to easily access maintenance treatments. However, a high risk of abuse exists, which demands extensive investigation and evaluation of these practices.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11772481     DOI: 10.1016/s0376-8716(01)00161-2

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  15 in total

1.  How a novel programme for increasing awareness of health professionals resulted in a 14% decrease in patients using excessive doses of psychotropic drugs in western France.

Authors:  C Victorri-Vigneau; G Basset; P Jolliet
Journal:  Eur J Clin Pharmacol       Date:  2006-02-28       Impact factor: 2.953

Review 2.  The pharmacological treatment of opioid addiction--a clinical perspective.

Authors:  Philipp Lobmaier; Michael Gossop; Helge Waal; Jorgen Bramness
Journal:  Eur J Clin Pharmacol       Date:  2010-02-19       Impact factor: 2.953

Review 3.  Harmonizing post-market surveillance of prescription drug misuse: a systematic review of observational studies using routinely collected data (2000-2013).

Authors:  Bianca Blanch; Nicholas A Buckley; Leigh Mellish; Andrew H Dawson; Paul S Haber; Sallie-Anne Pearson
Journal:  Drug Saf       Date:  2015-06       Impact factor: 5.606

4.  A New Way Forward in the Emergency Department.

Authors:  Evan S Schwarz; JoAn R Laes; Timothy J Wiegand
Journal:  J Med Toxicol       Date:  2019-07-05

5.  Assessment of abuse potential of benzodiazepines from a prescription database using 'doctor shopping' as an indicator.

Authors:  Vincent Pradel; Catherine Delga; Frank Rouby; Joëlle Micallef; Maryse Lapeyre-Mestre
Journal:  CNS Drugs       Date:  2010-07       Impact factor: 5.749

6.  Subjective effects of the nicotine lozenge: assessment of abuse liability.

Authors:  Elisabeth J Houtsmuller; Jack E Henningfield; Maxine L Stitzer
Journal:  Psychopharmacology (Berl)       Date:  2003-03-04       Impact factor: 4.530

7.  Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans.

Authors:  M A Huestis; E J Cone; S O Pirnay; A Umbricht; K L Preston
Journal:  Drug Alcohol Depend       Date:  2012-12-14       Impact factor: 4.492

Review 8.  Why buprenorphine is so successful in treating opiate addiction in France.

Authors:  M Fatseas; Marc Auriacombe
Journal:  Curr Psychiatry Rep       Date:  2007-10       Impact factor: 5.285

Review 9.  A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world.

Authors:  Michelle R Lofwall; Sharon L Walsh
Journal:  J Addict Med       Date:  2014 Sep-Oct       Impact factor: 3.702

10.  Comparison of prescriber evaluations and patient-directed self-reports in office-based practice for buprenorphine treatment of opiate-dependent individuals in France, 2002.

Authors:  Estelle Lavie; Mélina Fatséas; Jean-Pierre Daulouède; Cécile Denis; Jacques Dubernet; Laurent Cattan; Marc Auriacombe
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.